摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-乙氧基-4-氟-1-硝基苯 | 28987-44-2

中文名称
2-乙氧基-4-氟-1-硝基苯
中文别名
——
英文名称
2-ethoxy-4-fluoro-1-nitrobenzene
英文别名
4-fluoro-2-ethoxy-1-nitrobenzene;5-fluoro-2-nitrophenyl ethyl ether
2-乙氧基-4-氟-1-硝基苯化学式
CAS
28987-44-2
化学式
C8H8FNO3
mdl
MFCD04115630
分子量
185.155
InChiKey
LEMJFSSYFHTFFP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    35-37

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    55
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2909309090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    | 室温 |

SDS

SDS:5688a588f1e25531ad0bc296b918afe6
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Ethoxy-4-fluoro-1-nitrobenzene
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Ethoxy-4-fluoro-1-nitrobenzene
CAS number: 28987-44-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8FNO3
Molecular weight: 185.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-乙氧基-4-氟-1-硝基苯甲烷磺酸 、 palladium 10% on activated carbon 、 氢气potassium carbonate 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 10.75h, 生成 N-{2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine
    参考文献:
    名称:
    N- {2-甲氧基-4- [4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基} -N'-[2-(丙烷-2-磺酰基)苯基] -1的发现, 3,5-triazine-2,4-diamine(ASP3026),一种有效且选择性的间变性淋巴瘤激酶(ALK)抑制剂。
    摘要:
    间变性淋巴瘤激酶(ALK)是用于治疗棘皮动物微管相关蛋白样4(EML4)-ALK阳性非小细胞肺癌(NSCLC)的有效治疗靶标。我们合成了一系列的1,3,5-三嗪衍生物,并将ASP3026(14a)鉴定为有效的选择性ALK抑制剂。在异种移植了表达EML4-ALK的NCI-H2228细胞的小鼠中,每天一次口服14a表现出剂量依赖性抗肿瘤活性。在这里,描述了1,3,5-三嗪衍生物的合成和结构-活性关系(SAR)研究。
    DOI:
    10.1248/cpb.c17-00784
  • 作为产物:
    描述:
    参考文献:
    名称:
    Preparation of trifluoromethylphenyl nitrophenylethers
    摘要:
    一种制备三氟甲基苯基硝基苯醚的方法,包括将三氟甲基卤代苯与碱在共溶剂体系中处理,得到三氟甲基酚根,可以将其作为游离酚分离出来,或者与适当取代的卤代苯反应,制备二苯醚除草剂或其前体。
    公开号:
    US04259510A1
点击查看最新优质反应信息

文献信息

  • Piperazine compounds and medicinal use thereof
    申请人:Mitsubishi Pharma Corporation
    公开号:US06455528B1
    公开(公告)日:2002-09-24
    The present invention relates to a piperazine compound of the formula wherein R1 and R2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4 and R5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6 and R7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8 and R9 are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-&agr; production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-&agr; production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-&agr; production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-&agr; mediated diseases.
    本发明涉及一种哌嗪化合物,其化学式为 其中R1和R2分别为氢、卤素、低烷基、低烷氧基、氨基、取代氨基、硝基、羟基或氰基,R3、R4和R5分别为氢、卤素、低烷基、低烷氧基、硝基、氨基、取代氨基或羟基,R6和R7分别为氢、低烷基、受卤素取代的低烷基、芳基烷基、酰基或受卤素取代的低酰基,R8和R9分别为氢或低烷基,Y为低烷基烯基等,环A为苯基、嘧啶基、噻唑基、吡啶基、吡啉基或咪唑基,其药学上可接受的盐及含有这些化合物的药物制剂。本发明的化合物具有优越的TNF-α产生抑制作用和/或IL-10产生促进作用,由于它不含或仅显示对中枢神经系统有显著减少的作用,该化合物可用作高度安全和优越的TNF-α产生抑制剂和/或IL-10产生促进剂,并可用作预防或治疗由异常TNF-α产生引起的各种疾病的药剂,例如可用于治疗可通过IL-10治愈的慢性炎症性疾病、急性炎症性疾病、感染引起的炎症性疾病、自身免疫疾病、过敏性疾病和TNF-α介导的疾病。
  • Imidazopyridine Kinase Inhibitors
    申请人:Kuntz Kevin
    公开号:US20080300242A1
    公开(公告)日:2008-12-04
    The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    本发明提供了咪唑并吡啶化合物、含有该化合物的组合物,以及它们的制备方法和作为药物的使用方法。
  • [EN] (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES<br/>[FR] (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOZILINES
    申请人:NETHERLANDS TRANSLATIONAL RES CT B V
    公开号:WO2015155042A1
    公开(公告)日:2015-10-15
    The invention relates to a compound of Formula (I) wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.
    本发明涉及一种公式(I)的化合物,其中R1和R2独立地选自包括可选择性取代的(6-10C)芳基和(1-5C)杂芳基基团在内的组。这些化合物可用于药物组合物中,特别是在癌症治疗中。
  • 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
    申请人:齐鲁制药有限公司
    公开号:CN106995437A
    公开(公告)日:2017-08-01
    本发明涉及取代吲哚或吲唑嘧啶类衍生物及其制备方法、药物组合物和用途。具体地说,涉及式I化合物或其药学上可接受的盐或溶剂合物,其中,R1‑R7,X、Y的定义如说明书和权利要求书中所述。本发明还涉及式I化合物的制备方法,包括它的药物组合物以及它们的制药用途。本发明的式I化合物是有效的酪氨酸激酶不可逆抑制剂,特别是对EGFR‑T790M耐药肿瘤具有较强的抑制作用。
  • CARBINOL DERIVATIVES HAVING CYCLIC LINKER
    申请人:Yamaguchi Yuki
    公开号:US20100048610A1
    公开(公告)日:2010-02-25
    [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.
    提供一种新型的LXRβ激动剂,可用作预防和/或治疗动脉粥样硬化;动脉硬化,如糖尿病引起的动脉硬化;血脂异常;高胆固醇血症;与脂质相关的疾病;由炎性细胞因子引起的炎症性疾病;过敏性皮肤病;糖尿病;或阿尔茨海默病的治疗剂。【解决手段】以下一般式(I)所表示的羟甲基化合物或其盐,或其溶剂化合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐